These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 16166766)
21. Treatment paradigms for the newly diagnosed patient with multiple myeloma. Greipp P Semin Hematol; 2005 Oct; 42(4 Suppl 4):S16-21. PubMed ID: 16344097 [TBL] [Abstract][Full Text] [Related]
22. Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial. Dingli D; Rajkumar SV; Nowakowski GS; Gertz MA; Dispenzieri A; Lacy MQ; Hayman S; Fonseca R; Lust JA; Kyle RA; Greipp PR; Witzig TE Haematologica; 2005 Dec; 90(12):1650-4. PubMed ID: 16330438 [TBL] [Abstract][Full Text] [Related]
23. The current status of thalidomide in the management of multiple myeloma. Glasmacher A; von Lilienfeld-Toal M Acta Haematol; 2005; 114 Suppl 1():3-7. PubMed ID: 16166765 [TBL] [Abstract][Full Text] [Related]
24. Multiple myeloma: improved outcomes with new therapeutic approaches. Eshaghian S; Berenson JR Curr Opin Support Palliat Care; 2012 Sep; 6(3):330-6. PubMed ID: 22871979 [TBL] [Abstract][Full Text] [Related]
25. Low-dose thalidomide regimens in therapy of relapsed or refractory multiple myeloma. Zemanova M; Scudla V; Adam Z; Gregora E; Pour L; Minarik J; Pavlicek P; Pika T; Bacovsky J Neoplasma; 2008; 55(4):345-9. PubMed ID: 18505347 [TBL] [Abstract][Full Text] [Related]
26. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol]. Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962 [TBL] [Abstract][Full Text] [Related]
27. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study. Kaufman JL; Nooka A; Vrana M; Gleason C; Heffner LT; Lonial S Cancer; 2010 Jul; 116(13):3143-51. PubMed ID: 20564642 [TBL] [Abstract][Full Text] [Related]
28. Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma. Raje N; Hideshima T; Anderson KC Expert Rev Anticancer Ther; 2006 Sep; 6(9):1239-47. PubMed ID: 17020458 [TBL] [Abstract][Full Text] [Related]
29. Thalidomide in the treatment of multiple myeloma. Kastritis E; Dimopoulos MA Best Pract Res Clin Haematol; 2007 Dec; 20(4):681-99. PubMed ID: 18070713 [TBL] [Abstract][Full Text] [Related]
30. Clinical significance of cyclin D1, fibroblast growth factor receptor 3, and p53 immunohistochemistry in plasma cell myeloma treated with a thalidomide-based regimen. Kelley TW; Baz R; Hussein M; Karafa M; Cook JR Hum Pathol; 2009 Mar; 40(3):405-12. PubMed ID: 19070887 [TBL] [Abstract][Full Text] [Related]
31. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support. Vogl DT; Liu SV; Chong EA; Luger SM; Porter DL; Schuster SJ; Tsai DE; Perl A; Loren AW; Goldstein SC; Nasta SD; Andreadis C; Mangan PA; Hummel K; Siegel DL; Glatstein E; Stadtmauer EA Am J Hematol; 2007 Dec; 82(12):1071-5. PubMed ID: 17696204 [TBL] [Abstract][Full Text] [Related]
32. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival. Palumbo A; Attal M; Roussel M Clin Cancer Res; 2011 Mar; 17(6):1253-63. PubMed ID: 21411441 [TBL] [Abstract][Full Text] [Related]
33. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. Dimopoulos M; Spencer A; Attal M; Prince HM; Harousseau JL; Dmoszynska A; San Miguel J; Hellmann A; Facon T; Foà R; Corso A; Masliak Z; Olesnyckyj M; Yu Z; Patin J; Zeldis JB; Knight RD; N Engl J Med; 2007 Nov; 357(21):2123-32. PubMed ID: 18032762 [TBL] [Abstract][Full Text] [Related]
34. Thalidomide: present and future in multiple myeloma. Hussein MA Expert Rev Anticancer Ther; 2005 Feb; 5(1):25-31. PubMed ID: 15757435 [TBL] [Abstract][Full Text] [Related]
35. Treatment of refractory multiple myeloma with vincristine, adriamycin, dexamethasone, and with repeated application of cyclophosphamide (C-VAD). Adam Z; Elbl L; Vorlicek J; Hájek R; Hájek D; Hejlová N; Králová E; Novotná H Acta Med Austriaca; 1994; 21(4):111-5. PubMed ID: 7871966 [TBL] [Abstract][Full Text] [Related]
36. Novel agents for relapsed and/or refractory multiple myeloma. Thomas SK; Richards TA; Weber DM Cancer J; 2009; 15(6):485-93. PubMed ID: 20010168 [TBL] [Abstract][Full Text] [Related]